Title:
PEGYLATED BORON CLUSTER COMPOUND, ANTITUMOR AGENT INCLUDING PEGYLATED BORON CLUSTER COMPOUND, AND SENSITIZER INCLUDING PEGYLATED BORON CLUSTER
Document Type and Number:
WIPO Patent Application WO/2020/040296
Kind Code:
A1
Abstract:
As an enhancer for boron neutron capture therapy, a compound is anticipated which has ideal effects and physical properties in terms of the therapeutic principles of boron neutron capture therapy. As a solution, the present invention provides: a PEGylated boron cluster compound characterized in that a boron cluster having a thiol group binds to a multi-arm polyethylene glycol with a maleimide functional group; an antitumor agent including a PEGylated boron cluster compound; and an enhancer including a PEGylated boron cluster compound used for boron neutron capture therapy.
Inventors:
SHIRAKAWA MAKOTO (JP)
TOMIDA HISAO (JP)
TAKEUCHI RYOTA (JP)
HORI HITOSHI (JP)
KAMEGAWA NOBUYUKI (JP)
TOMIDA HISAO (JP)
TAKEUCHI RYOTA (JP)
HORI HITOSHI (JP)
KAMEGAWA NOBUYUKI (JP)
Application Number:
PCT/JP2019/033062
Publication Date:
February 27, 2020
Filing Date:
August 23, 2019
Export Citation:
Assignee:
MORITA PHARMACEUTICAL IND LTD (JP)
FUKUYAMA UNIV (JP)
FUKUYAMA UNIV (JP)
International Classes:
A61K31/69; C08G65/337; A61K31/74; A61K41/00; A61P35/00
Domestic Patent References:
| WO2017164334A1 | 2017-09-28 | |||
| WO2014030715A1 | 2014-02-27 |
Other References:
KIKUCHI, SHUNSUKE ET AL.: "Maleimide- functionalized closo-dodecaborate albumin conjugates (MID-AC): Unique ligation at cysteine and lysine residues enables efficient boron delivery to tumor for neutron capture therapy", JOURNAL OF CONTROLLED RELEASE, vol. 237, 2016, pages 160 - 167, XP029679996, DOI: 10.1016/j.jconrel.2016.07.017
Attorney, Agent or Firm:
HIRAKI & ASSOCIATES (JP)
Download PDF: